Insulin antibodies are immune proteins the body makes that bind to insulin—either produced naturally or injected. They can change insulin’s availability and action, causing unpredictable blood-glucose control, occasional hypoglycaemia, or reduced insulin effectiveness (insulin resistance). They’re detected by blood tests; clinical significance varies depending on antibody levels, symptom timing, and the type of insulin exposure.

The four principal autoantibodies used to detect autoimmune (type 1) diabetes are: glutamic acid decarboxylase antibodies (GAD65), insulin autoantibodies (IAA), insulinoma-associated antigen‑2 antibodies (IA‑2/ICA512), and zinc transporter 8 antibodies (ZnT8). They’re measured by blood tests and help confirm autoimmune diabetes, predict risk, and guide prognosis and treatment planning.

If insulin antibodies cause unpredictable hypoglycaemia or resistance, see an endocrinologist. Management may include switching insulin type (recombinant human or analogs), using insulin pump therapy, or adjusting dose. For severe, refractory cases, short-term immunosuppression, plasmapheresis or IVIG can be considered. Monitor antibody titers, glucose control and C‑peptide; individualized specialist guidance is essential.

A result of 0.4 for insulin antibodies is generally at or near common laboratory cutoffs, so it can be interpreted as borderline or low‑positive depending on the lab’s reference range. In people not using insulin it may suggest an autoimmune response linked to type 1 diabetes; in those treated with insulin it often reflects antibodies to injected insulin. Clinical correlation with your doctor is needed.

A normal insulin antibody result is essentially negative — below the laboratory’s assay cutoff. Most labs report “negative” or values under the reference range; when numeric, thresholds often run around <1.0–1.5 U/mL or an assay-specific index below the positive cutoff. Detectable or elevated antibodies should prompt clinical review for prior insulin exposure or possible autoimmune insulin syndrome.

Costs vary by country and setting. In the United States a private insulin antibody (IAA) test typically ranges about $50–$200; in the United Kingdom it’s usually provided free on the NHS but costs roughly £40–£120 privately; in India private labs charge approximately ₹500–₹2,000. Prices depend on the laboratory, location, and whether testing is done through public healthcare or a private provider.